{"paper_id":"a119aa3f-b347-474e-9e17-f9dc2ed0e509","body_text":"Abstract\nMatrix metalloproteinases (MMPs) belong to a multigenic family of proteolytic enzymes with great structural variability which provide a complex intervention in pathophysiological conditions. Our review is focused on both MMPs key role in physiological reproductive events, such as embryo implantation, uterine involution, normal endometrial cycle, and on their role in the main endometrial pathologies. MMPs activity is closely regulated by tissue inhibitors of MMPs (TIMPs). MMP: TIMP imbalance has been incriminated in various pathological conditions, including endometrial cancer and endometriosis. Accumulated data support the involvement of a large spectrum of MMPs and TIMPs in endometrial carcinogenesis. Strong MMP-2 and weak TIMP-2 tissue immunoexpressions have a powerful prognosis value, while MMP-9 high expression suggests its important involvement in endometrial tumor invasiveness. Endometriosis development implies an accumulation of events showing partial overlap with endometrial carcinogenesis and invasion, requiring MMPs involvement. Therefore, increased levels of several MMPs have been detected in peritoneal fluid and/or endometrial tissue of patients diagnosed with endometriosis. Endometriotic mesenchymal stem cells (MSCs) may be involved in the pathogenesis of endometriosis due to their upregulated expression for markers of migration and angiogenesis, such as MMP-2, MMP-3, MMP-9, and VEGF. The hypothesis of therapeutic benefits of synthetic MMPs inhibitors, added to the progesterone or progestins action, has been based on the complex MMPs involvement in endometrial pathology. Future research is necessary to elucidate the complex interactions between molecules involved in proliferation, angiogenesis and apoptosis, opening new perspectives in the early diagnosis and treatment of endometrial neoplasia and endometriosis.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nVisse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 92:827–839\nIi M, Yamamoto H, Adachi Y et al (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 231:20–27\nBrummer O, Bohmer G, Hollwitz B et al (2002) MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation-an immunohistochemical study. Gynecol Oncol 84:222–227\nOverall CM (2002) Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 22:51–86\nJohansson N, Ala-Aho R, Uitto V et al (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 113:227–235\nCurry TE Jr, Osteen KG (2003) The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 24:428–465\nFolgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411–424\nHashizume K (2007) Analysis of utero-placental-specific molecules and their functions during implantation and placentation in the bovine. J Reprod Dev 53:1–11\nOsteen KG, Igarashi TM, Bruner-Tran KL (2003) Progesterone action in the human endometrium: induction of a unique tissue environment which limits matrix metalloproteinase (MMP) expression. Front Biosci 8:78–86\nYadav L, Puri N, Rastogi V et al (2014) Matrix metalloproteinases and cancer—roles in threat and therapy. Asian Pac J Cancer Prev 15:1085–1091\nShiomi T, Okada Y (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 22:145–152\nAmalinei C, Caruntu ID, Balan R (2007) Biology of metalloproteinases. Rom J Morphol Embryol 48:316–320\nWiseman BS, Sternlicht MD, Lund LR et al (2003) Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol 162:1123–1133\nBouloumie A, Sengenes C, Portolan G et al (2001) Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 50:2080–2086\nLambert V, Wielockx B, Munaut C et al (2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17:2290–2292\nSolberg H, Rinkenberger J, Danø K et al (2003) A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 130:4439–4450\nEnglish JL, Kassiri Z, Koskivirta I et al (2006) Individual TIMP deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 281:10337–10346\nLee MH, Murphy G (2004) Matrix metalloproteinases at a glance. J Cell Science 117:4015–4016\nMannello F, Gazzanelli G (2001) Tissue inhibitors of metalloproteinases and programmed cell death: Conundrums, controversies and potential implications. Apoptosis 6:479–482\nCollette T, Bellehumeur C, Kats R et al (2004) Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod 19:1257–1264\nSeo DW, Li H, Guedez L et al (2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114:171–180\nWang WM, Ge G, Lim NH et al (2006) TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem J 398:515–519\nYu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176\nQi JH, Ebrahem Q, Moore N et al (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9:407–415\nLiu K, Wahlberg P, Hagglund AC, Ny T (2003) Expression pattern and functional studies of matrix degrading proteases and their inhibitors in the mouse corpus luteum. Mol Cell Endocrinol 31:131–140\nOh J, Seo DW, Diaz T et al (2004) Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 64:9062–9069\nBaker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727\nJiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 28:2245–2252\nVelasco G, Pendás AM, Fueyo A et al (1999) Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 274:4570–4576\nFreitas S, Meduri G, Le Nestour E et al (1999) Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium. Biol Reprod 61:1070–1082\nD’Ippolito S, Marana R, Di Nicuolo F et al (2012) Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS ONE 7(1):e29660. doi:10.1371/journal.pone.0029660\nLockwood CJ (2011) Mechanisms of normal and abnormal endometrial bleeding. Menopause 18:408–411\nCornet PB, Galant C, Eeckhout Y et al (2005) Regulation of matrix metalloproteinase-9/gelatinase B expression and activation by ovarian steroids and LEFTY-A/endometrial bleeding-associated factor in the human endometrium. J Clin Endocrinol Metab 90:1001–1011\nNissi R, Talvensaari-Mattila A, Kotila V et al (2013) Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure. Reprod Biol Endocrinol 11:2. doi:10.1186/1477-7827-11-2\nMoindjie H, Santos ED, Loeuillet L et al (2014) Preimplantation factor (PIF) promotes human trophoblast invasion. Biol Reprod 91:118. doi:10.1095/biolreprod.114.119156\nZhuang Y, Qian Z, Huang L (2014) Elevated expression levels of matrix metalloproteinase-9 in placental villi and tissue inhibitor of metalloproteinase-2 in decidua are associated with prolonged bleeding after mifepristone-misoprostol medical abortion. Fertil Steril 101:166–171\nLockwood CJ, Basar M, Kayisli UA et al (2014) Interferon-γ protects first-trimester decidual cells against aberrant matrix metalloproteinases 1, 3, and 9 expression in preeclampsia. Am J Pathol 184:2549–2559\nIshikawa T, Harada T, Kubota T, Aso T (2007) Testosterone inhibits matrix metalloproteinase-1 production in human endometrial stromal cells in vitro. Reproduction 133:1233–1239\nGraesslin O, Cortez A, Fauvet M et al (2006) Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 17:637–645\nGalant C, Berliere M, Dubois D et al (2004) Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol 165:83–94\nNagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562–573\nYi YC, Chou PT, Chen LY et al (2010) Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. Clin Chem Lab Med 48:337–344\nUeno H, Yamashita K, Azumano I et al (1999) Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 84:470–477\nMäätä M, Soini Y, Liakka A, Autio-Harmainen H (2000) Localisation of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am J Clin Pathol 114:402–411\nHojilla CV, Mohammed FF, Khokha R (2003) Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 10:1817–1821\nAmalinei C, Caruntu ID, Balan R et al (2008) Contribution of immunohistochemistry and flow-cytometry in the study of endometrial pathology. Rev Med Chir Soc Med Nat Iasi 112:437–448\nAmalinei C, Caruntu ID, Giusca SE, Balan RA (2010) Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 51:215–228\nEgeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174\nAmalinei C, Cianga C, Balan R et al (2011) Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium. Ann Anat 193:43–55\nPark DW, Ryu HS, Choi DS et al (2001) Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol Oncol 82:442–449\nHonkavuori M, Talvensaari-Mattila A, Soini Y et al (2007) MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol 104:217–221\nMcLaughlin B, Weiss JB (1996) Endothelial-cell-stimulating angiogenesis factor (ESAF) activates progelatinase A (72 kDa type IV collagenase), prostromelysin 1 and procollagenase and reactivates their complexes with tissue inhibitors of metalloproteinases: a role for ESAF in non-inflammatory angiogenesis. Biochem J 317:739–745\nAglund K, Rauvala M, Puistola U et al (2004) Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer—MMP-9 correlates to the grade and the stage. Gynecol Oncol 94:699–704\nHonkavuori-Toivola M, Talvensaari-Mattila A, Soini Y et al (2012) Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma. Tumor Biol 33:935–941\nHonkavuori-Toivola M, Santala M, Soini Y et al (2013) Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma. Dis Markers 35:261–266\nTalvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T (2005) Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res 25:4101–4105\nLaas E, Ballester M, Cortez A et al (2014) Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer. Gynecol Oncol 133:205–210\nGrybos A, Bar J (2014) The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer. Folia Histochem Cytobiol 52:187–194\nJedryka M, Chrobak A, Chelmonska-Soyta A et al (2012) Matrix metalloproteinase (MMP)-2 and MMP-9 expression in tumor infiltrating CD3 lymphocytes from women with endometrial cancer. Int J Gynecol Cancer 22:1303–1309\nSrdelić Mihalj S, Kuzmić-Prusac I, Zekić-Tomaš S et al (2014) Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value. Histopathology 17. doi:10.1111/his.12633\nMannelqvist M, Stefansson IM, Wik E et al (2012) Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 12:169\nNishi H, Kuroda M, Isaka K (2013) Estrogen and estrogen receptor induce matrix metalloproteinase-26 expression in endometrial carcinoma cells. Oncol Rep 30:751–756\nNabeshima K, Iwasaki H, Nishio J et al (2006) Expression of emmprin and matrix metalloproteinases (MMPs) in peripheral nerve sheath tumors: emmprin and membrane-type (MT)1-MMP expressions are associated with malignant potential. Anticancer Res 26:1359–1367\nYan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93:199–204\nMuramatsu T, Miyauchi T (2003) Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 18:981–987\nTang Y, Nakada MT, Kesavan P et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199\nUeda K, Yamada K, Urashima M et al (2007) Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol Rep 17:731–735\nNakamura K, Kodama J, Hogo A, Hiramatsu Y (2012) Role of emmprin in endometrial cancer. BMC Cancer 12:191–201\nYang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829\nYang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939\nKhoufache K, Bazin S, Girard K et al (2012) Macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo. PLoS ONE 7:e37264\nLondero AP, Calcagno A, Grassi T et al (2012) Survivin, MMP-2, MT1-MMP, and TIMP-2: their impact on survival, implantation, and proliferation of endometriotic tissues. Virchows Arch 461:589–599\nSuzumori N, Ozaki Y, Ogasawara M, Suzumori K (2001) Increased concentrations of cathepsin D in peritoneal fluid from women with endometriosis. Mol Hum Reprod 7:459–462\nMizumoto H, Saito T, Ashihara K et al (2002) Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci 71:259–273\nScotti S, Regidor PA, Schindler AE, Winterhager E (2000) Reduced proliferation and cell adhesion in endometriosis. Mol Hum Reprod 6:610–617\nChen GT, Tai CT, Yeh LS et al (2002) Identification of the cadherin subtypes present in the human peritoneum and endometriotic lesions: potential role for P-cadherin in the development of endometriosis. Mol Reprod Dev 62:289–294\nUeda M, Yamashita Y, Takehara M et al (2002) Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol 16:391–402\nMoreno-Bueno G, Gamallo C, Pérez-Gallego L et al (2001) beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10:116–122\nJana SK, Banerjee P, Mukherjee R et al (2013) HOXA-11 mediated dysregulation of matrix remodeling during implantation window in women with endometriosis. J Assist Reprod Genet 30:1505–1512\nMalvezzi H, Aguiar VG, Paz CC et al (2013) Increased circulating MMP-2 levels in infertile patients with moderate and severe pelvic endometriosis. Reprod Sci 20:557–562\nAntsiferova Y, Sotnikova N (2012) The local immune mechanisms involved in the formation of endometriotic lesions. In: Chaudhury K, Chakravarty B (eds) Endometriosis—basic concepts and current research trends. ISBN 978-953-51-0524-4, 11: 211-244. doi:10.5772/29965\nYeaman GR, Collins JE, Lang GA (2002) Autoantibody responses to carbohydrate epitopes in endometriosis. Ann N Y Acad Sci 955:174–182\nCominelli A, Gaide Chevronnay HP, Lemoine P et al (2014) Matrix metalloproteinase-27 is expressed in CD163+/CD206+ M2 macrophages in the cycling human endometrium and in superficial endometriotic lesions. Mol Hum Reprod 20:767–775\nTrovó de Marqui AB (2012) Genetic polymorphisms and endometriosis: contribution of genes that regulate vascular function and tissue remodeling. Rev Assoc Med Bras 58:620–632\nIarmolinskaia MI, Molotkov AS, Bezhenar VF et al (2014) Association of matrix metalloproteinases’ polymorphisms of MMP3 and MMP9 with development of genital endometriosis. Genetika 50:230–235\nYuan C, Zhang L, Gao Y et al (2014) DNA demethylation at the promoter region enhances the expression of MMP-9 in ectopic endometrial stromal cells of endometriosis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 30:1258–1261\nKoippallil Gopalakrishnan Nair AR, Pandit H, Warty N, Madan T (2015) Endometriotic mesenchymal stem cells exhibit a distinct immune phenotype. Int Immunol 27:195–204\nFierro IM, Colgan SP, Bernasconi G et al (2003) Lipoxin A4 and aspirin-triggered 15-epi-LipoxinA4 inhibit human neutrophil nigration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol 170:2688–2694\nKumar R, Clerc AC, Gori I et al (2014) Lipoxin A4 prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E2 production and estrogen signaling. PLoS ONE 24:e89742\nWu R, Zhou W, Chen S et al (2014) Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway. Br J Pharmacol 171:4927–4940\nBayoglu Tekin Y, Guven S, Kirbas A et al (2015) Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? Eur J Obstet Gynecol Reprod Biol 184:1–6\nTamaki K, Tanzawa K, Kurihara S et al (1995) Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Chem Pharm Bull 43:1883–1893\nConway JG, Trexler SJ, Wakefield JA et al (1996) Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastatsis. Clin Exp Metastasis 14:115–124\nBrown PD (1998) Matrix metalloproteinase inhibitors. Angiogenesis 1:142–154\nBottomley KM Borkakoti N, Bradshaw D et al (1997) Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors. Biochem J 323:483–488\nRigot V, Marbaix E, Lemoine P et al (2001) In vivo perimenstrual activation of progelatinase B (proMMP-9) in the human endometrium and its dependence on stromelysin 1 (MMP-3) ex vivo. Biochem J 358:275–280\nSalamonsen LA, Butt AR, Hammond FR et al (1997) Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab 82:1409–1415\nPrifti S, Lelle I, Zhong G et al (2004) Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin. Gynecol Endocrinol 18:23–27\nHampton AL, Nie G, Salamonsen LA (1999) Progesterone analogues similarly modulate endometrial matrix metalloproteinase-1 and matrixmetalloproteinase-3 and their inhibitor in a model for long-term contraceptive effects. Mol Hum Reprod 5:365–371\nRawdanowicz TJ, Hampton AL, Nagase H et al (1994) Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab 79:530–536\nSinger CF, Marbaix E, Lemoine P et al (1999) Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts. Eur J Biochem 259:40–45\nBruner KL, Rodgers WH, Gold LI et al (1995) Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 92:7362–7366\nZhang Y, McCluskey K, Fujii K, Wahl LM (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 161:3071–3076\nLau TM, Witjaksono J, Affandi B, Rogers PA (1996) Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users. Hum Reprod 11:2629–2634\nMertens HJ, Heineman MJ, Koudstaal J et al (1996) Androgen receptor content in human endometrium. Eur J Obstet Gynecol Reprod Biol 70:11–13\nWilson CM, McPhaul MJ (1996) A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 120:51–57\nSchneikert J, Peterziel H, Defossez PA et al (1996) Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 271:23907–23913\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2017 Springer Nature Singapore Pte Ltd.\nAbout this chapter\nCite this chapter\nAmalinei, C., Căruntu, ID., Giuşcă, S.E., Balan, R.A. (2017). Complex Mechanisms of Matrix Metalloproteinases Involvement in Endometrial Physiology and Pathology—An Update. In: Chakraborti, S., Chakraborti, T., Dhalla, N. (eds) Proteases in Human Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-10-3162-5_3\nDownload citation\nDOI: https://doi.org/10.1007/978-981-10-3162-5_3\nPublished:\nPublisher Name: Springer, Singapore\nPrint ISBN: 978-981-10-3161-8\nOnline ISBN: 978-981-10-3162-5\neBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)","source_license":"CC0","license_restricted":false}